Some forms of breast cancer unfortunately they can have a relapse, the cd relapse. A drug, theOlaparib, according to a recent research, it would be able to reduce the incidence, to have an invasive disease or the onset of new tumors or death by 42%.
The study was published on the New England Journal of medicine.
Olaparib: here are the benefits of drug therapy
It was thanks to the project OlympiA presented in one of the main sessions of the annual congress ofAmerican Society of Clinical Oncology (Asco), that this important milestone was achieved: ” His conclusions clearly indicate the importance of genetic testing for BRCA mutations in patients with an early breast cancer diagnosis but at high risk of relapse because its outcomes can have a decisive impact on the choice of treatment to be undertaken. , including a PARP inhibitor medicine in the treatment “ he pointed out Lori J Pierce, president of Asco.
OlympiA includes a phase three multicenter study, the last before the authorization of a new therapy, which involved 1836 women with high-risk, HER2-negative breast cancer and inherited mutations of the BRCA1 and BRCA2 genes with the aim of testing the efficacy and safety of olaparib tablets versus placebo.
The subjects involved in the research were given the current standard therapy (surgery and chemotherapy, before or after surgery, with the possible addition of radiotherapy when necessary) and have been divided into two groups: one also received olaparib for a year, the other placebo. The results showed that after three years from the end of treatment, 85.9% of patients treated with the additional drug are alive and free from invasive breast cancer and other cancers compared to 77.1% in the placebo group.
Olaparib was also useful for a statistically significant and clinically important improvement in distant disease-free survival and reduced the risk of distant recurrence or death by 43%. As for the side effects, there were: nausea (57%), fatigue (40%), anemia (23%), vomiting (23%) and about 10% of subjects treated with the additional drug stopped early. treatment because of the side effects themselves.
Michelino De Laurentiis, director of Department of Senology of the Pascale Cancer Institute of Napolthe and lead author of the OlympiA study, said: “”THEn presence of a mutation BRCA, the tumor of the breast tends to occur in a younger population than the mean age of diagnosis. Despite research advances, the risk of relapse, even in the presence of early diagnosis, is very high and new targeted therapeutic approaches are needed that can help keep the disease at bay. Based on the first results presented at the Asco congress, olaparib has the potential to be used as an adjunct to all standard initial breast cancer treatments providing an additional and lasting clinical benefit ”.
It is important to inform those who may be interested that Olaparib is already available and approved in Italy for the treatment, in the presence of the BRCA mutation, of metastatic triple negative breast cancer and advanced ovarian cancer on multiple lines of treatment.
“The results of the OlympiA study represent a potential step forward for patients with early, high-risk breast cancer – concludes Laura Cortesi, responsible for Oncological Genetics Department at the Oncology Department of the University Hospital of Modena and member of the working group for the drafting of recommendations for the implementation of the BRCA test in patients with breast cancer.
“These new data support the importance of the diagnostic test for BRCA1 and 2 mutations: in addition to determining the state of the hormone receptor and the expression of the HER2 protein, they allow better patient management and at the same time provide information useful for his family “. The mutation, which can be hereditary and present within a family of relatives, is in fact linked to a greater probability of getting breast, ovarian, prostate and pancreatic cancer, which is why the test can he to be indicated, in determined cases, also to people healthy of the family”.
Breast cancer is among the most frequent in Italy: in 2020, almost 55,000 new cases are estimated and the presence of a BRCA mutation is detected in about 5% of patients. Today it is possible to apply personalized therapies, through certain alterations of the genes or proteins identified in the single neoplasm, which become the target of an individualized therapy.